Technology | November 06, 2014

Cardinal Health MynxGrip Vascular Closure Device Receives FDA Approval for Venous Indication

Device now approved for use to seal femoral arterial and femoral venous access sites

November 6, 2014 — Cardinal Health announced that its MynxGrip Vascular Closure Device recently received U.S. Food and Drug Administration (FDA) approval for use to close femoral veins. The MynxGrip device is now indicated for use to seal 5, 6 and 7 French femoral arterial and femoral venous access sites.

The venous indication could help interventional healthcare providers increase efficiency of their labs and minimize potential complications associated with venous closure by replacing the need for manual compression. The MynxGrip device is intended to reduce times to hemostasis and ambulation, thereby potentially shortening post-procedure recovery times.

The MynxGrip Vascular Closure Device utilizes the proprietary, extravascular Grip sealant that actively adheres to the vein for a secure mechanical closure and dissolves within 30 days, leaving nothing permanently behind in the healed vein. The safety profile of this secure extravascular sealant makes the MynxGrip device uniquely suited for venous closure, as it does not leave behind an intravascular component. 

"The gentle deployment and secure extravascular sealant make the MynxGrip device an excellent option for closing femoral veins,” said Sanjay Srivatsa, M.D., director, Heart Artery and Vein Center, Fresno, Calif.  “I feel confident that this indication will change the way interventionalists and electrophysiologists approach venous access sites, enabling them to close their more complex cases on the table, and thereby helping to increase efficiency and throughput in busy interventional laboratories."

The new venous indication does not include any changes to the existing MynxGrip Vascular Closing Device. Cardinal Health is mailing new instructions for use documents and patient brochures to all current MynxGrip users and those users can immediately begin using the existing device to close femoral veins.

For more information: www.accessclosure.com

Related Content

ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Sponsored Content | Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
New Data Demonstrate Clinical and Quality-of-Life Benefits for VenaSeal Closure System in Venous Reflux Disease Patients
News | Venous Therapies| May 05, 2017
Medtronic plc recently announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data...
News | Venous Therapies| April 26, 2017
A new Varicose Vein Registry has begun producing useful outcomes information, as reported in the May edition of the...
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
Vivasure Medical, Closure Device, Series C financing
News | Vascular Closure Devices| September 12, 2016
September 12, 2016 — Vivasure Medical announced last week that the company has completed a Series C financing of €16.
News | Venous Therapies| September 12, 2016
Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow...
Rex medical, Closer Vascular Sealing System, VSS, vascular closure, bioresorbable vascular closure device

A close up view of the Rex Medical Closer Vascular Sealing System components.

Technology | Vascular Closure Devices| August 03, 2016
August 3, 2016 — The U.S.
Overlay Init